NEW YORK (Reuters Health) — HER2-low-positive breast cancer, readily identified by standardized central pathology, is a distinct subtype with a specific biology and different response to therapy and...

The PD-L1 inhibitor atezolizumab (Tecentriq) combined with carboplatin has shown signs of clinical activity in women with metastatic invasive lobular breast cancer (ILC) according to the first results...